NCT02698553 - A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 23, 2016

Primary Completion Date

June 29, 2016

Study Completion Date

June 29, 2016

Conditions

Depressive Disorder, Major

Interventions

DRUG

Bupropion HCl XL tablet 150mg

The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.

DRUG

Bupropion HCl XL tablet 300mg

The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.

Trial Locations (1)

200030

GSK Investigational Site, Shanghai